Author: OurCrowd

OurCrowd’s portfolio company Replay Technologies featured in VentureBeat

OurCrowd’s portfolio company Replay Technologies was featured in VentureBeat, a leading technology website. Free Dimensional Video (freeD), developed by Replay Technologies, provides sports fans with an immersive real-life viewing experience with a vision of true virtual reality sports viewing. Replay Technologies has installed 36 5K high-definition cameras around Levi’s Stadium in Santa Clara, Calif., where the Denver Broncos and the Carolina Panthers will square off on Sunday. Those cameras can capture the action from almost 360 degrees. What’s more, CBS will be able to “freeze” the action and rotate the view so fans can get a clear line of sight to the action. Referees will even be able to get a clear view of the ball when doing replays for possible penalty calls. Dubbed Free-D, the replay video can make fans anywhere feel like they’ve got the same view as the lucky ones seated on the sidelines. Each camera is connected to a dedicated Xeon E5-26XX server, powered by Intel. Those servers take the video from the different angles and render it into 3D voxels, or a 3D-animated view...

Read More

Anatomy of OurCrowd’s Innovative MedTech Portfolio [Infographic]

How do you feel today? Feeling good? Consider for a second your local hospital or doctor’s clinic: The ER, the OR, the lab, the tabletop devices, the drugs and wearables. With constant updates and developments of tech solutions servicing the healthcare and medical industries, the future is bright for MedTech sector, and exciting for both entrepreneurs and investors. Medical technologies are a key focus area for OurCrowd’s investment strategy and comprise over 18% of our overall portfolio. In fact, our first company to exit was ReWalk Robotics (NASDAQ: RWLK), an exoskeleton for people with spinal cord injuries, in 2014. As we continue to build, grow, and exit medical technologies (among others), we’re pleased to share the following infographic capturing the scope of some of the amazing MedTech companies in OurCrowd’s portfolio, proving themselves in this growing industry. Feel good about this infographic? Share if you find it helpful! To find out more about digital health, MedTech, and other investment opportunities on our platform, contact our Investor Relations team or visit our...

Read More

OurCrowd’s portfolio company The Bouqs featured in TechCrunch

Leading technology website, TechCrunch, featured OurCrowd’s portfolio company The Bouqs. The company is a direct-to-consumer e-commerce platform for purchasing flowers, that uses technology to restructure the supply chain from A to Z. We’re a week and a half away from Valentine’s Day, one of the biggest days for flower purchases everywhere and probably the best time for The Bouqs, an on-demand-ish flower startup to announce it pulled in $12 million in Series B financing. The Bouqs is not a name that rolls off the tongue, but it promises better pricing and next day shipping with flowers that last longer. The Bouqs raised $415,004 from OurCrowd investors in December 2015. Read more on...

Read More

OurCrowd’s portfolio company Billguard featured in The Times of Israel

OurCrowd’s portfolio company BillGuard was featured in The Times of Israel, an English-language news website covering Israel, the region & the Jewish world. BillGuard identifies fraud and “grey” charges, which cost consumers over $25B annually, by analyzing crowdsourcing transaction data from its millions-strong user base. Many Israeli entrepreneurs ask themselves if they have what it takes to succeed in Silicon Valley. But perhaps the question is whether or not entrepreneurs from the US have what it takes to make it in Israel. “The acquisition of BillGuard has been a real eye-opener,” said Aaron Vermut, CEO of San Francisco-based Prosper, who is in Israel for the first time in three decades to visit his company’s new Israeli subsidiary, which tracks credit card spending and monitoring. BillGuard raised $3,896,064 from OurCrowd investors in August 2014. Read more on The Times of Israel...

Read More